Detalhe da pesquisa
1.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Br J Cancer
; 128(8): 1503-1513, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36759720
2.
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Gynecol Oncol
; 155(2): 186-191, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31519320
3.
Combined chemotherapy and pembrolizumab salvages multi-chemotherapy agent and avelumab resistant choriocarcinoma: A case report.
Gynecol Oncol Rep
; 49: 101259, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37636493